EC Number |
BRENDA No. |
Title |
Journal |
Volume |
Pages |
Year |
Organism |
PubMed ID |
---|
3.1.4.35 | 750479 |
Carboxyamidotriazole A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases |
Eur. J. Pharmacol. |
746 |
14-21 |
2015 |
Mus musculus |
25446933 |
3.1.4.35 | 750479 |
Carboxyamidotriazole A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases |
Eur. J. Pharmacol. |
746 |
14-21 |
2015 |
Rattus norvegicus |
25446933 |
3.1.4.35 | 750045 |
Identification of novel PDEdelta interacting proteins |
Bioorg. Med. Chem. |
26 |
1426-1434 |
2018 |
Homo sapiens |
28935183 |
3.1.4.35 | 751213 |
Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development |
J. Enzyme Inhib. Med. Chem. |
32 |
311-330 |
2017 |
Homo sapiens |
28150511 |
3.1.4.35 | 711409 |
1-(2-(2,2,2-Trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors |
Bioorg. Med. Chem. Lett. |
20 |
3125-3128 |
2010 |
Homo sapiens |
20400309 |
3.1.4.35 | 667521 |
A novel role for a Drosophila homologue of cGMP-specific phosphodiesterase in the active transport of cGMP |
Biochem. J. |
393 |
481-488 |
2006 |
Drosophila sp. (in: flies) |
16232123 |
3.1.4.35 | 711557 |
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia |
BJU Int. |
106 |
674-680 |
2010 |
Homo sapiens |
20184577 |
3.1.4.35 | 135318 |
Activation of retinal rod cyclic GMP-phosphodiesterase by transducin: characterization of the complex formed by phosphodiesterase inhibitor and transducin alpha-subunit |
Proteins Struct. Funct. Genet. |
1 |
188-193 |
1986 |
Bos taurus |
2835763 |
3.1.4.35 | 712630 |
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition |
J. Heart Lung Transplant. |
28 |
676-682 |
2009 |
Homo sapiens |
19560695 |
3.1.4.35 | 650180 |
Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP |
Biochemistry |
41 |
9672-9679 |
2002 |
Rattus norvegicus |
12135389 |